Below we list the key items related to the turnaround effort and to the development of VI-0106. ‣ MAA submitted for Qsymia in Europe – October 2019 ‣ Launch of telemedicine – 4Q:19 & 1Q:20 ‣ Reduce, refinance and repay debt - 2020 ‣ Launch of Qsymia in South Korea – March 2020 ‣ Increase licensing agreements for avanafil – 2020 ‣ Introduce Qsymia Health Platform to managed care and large self-insured employers – 2020 ‣ Begin contract with large national PBM for Pancreaze – July 2020 ‣ Response from EMA for Qsymia – 2020 ‣ Submit IND for VI-0106 – 2H:20 ‣ Launch Phase II study for VI-0106 – 1Q:21 Summary We are in the seventh quarter of the ten quarter turnaround effort and have seen evidence of improvement and opportunity that can convert Vivus into a profitable enterprise. Our forecasts had anticipated that the debt issue would be resolved by now; however, disruptions to the credit market from the shutdown related to the coronavirus have extended the refinancing for at least another month.